Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 2003

Chang Alfred E, Li Qiao, Jiang Guihua, Sayre Donna M, Braun Thomas M, Redman Bruce G

Abstract excerpt

PURPOSE: Previous preclinical and clinical studies have demonstrated that autologous tumor vaccines can induce relatively specific tumor-reactive T cells in draining lymph nodes. The adoptive transfer of these cells can result in tumor regression. PATIENTS AND METHODS: Patients with stage IV renal cell cancer (RCC) were vaccinated with irradiated autologous tumor cells admixed with Calmette-Guérin bacillus....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adoptive Transfer
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to CD3 Complex

Share to Immunity, Cellular

Share to Immunotherapy, Adoptive

Share to Infusions, Intravenous

Share to Lymphocytes, Tumor-Infiltrating

Share to Mycobacterium bovis

Source

Identifiers

PMID: 12610189
DOI: 10.1200/JCO.2003.08.023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.PMID 12610189Read ↗

Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.Semantic proximity Read ↗

Immunological effects of BCG as an adjuvant in autologous tumor vaccines.Semantic proximity Read ↗

Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.Semantic proximity Read ↗

Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.Semantic proximity Read ↗

Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer.Semantic proximity Read ↗

Phase I Study of Autologous Tumor Vaccines Transduced with the GM-CSF Gene in Four Patients with Stage IV Renal Cell Cancer in Japan: Clinical and Immunological FindingsSemantic proximity Read ↗

Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.Semantic proximity Read ↗

A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer.Semantic proximity Read ↗

Cancer vaccines: moving beyond current paradigms.Semantic proximity Read ↗

Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.Semantic proximity Read ↗

[Adoptive immunotherapy and metastasized cancer of the kidney. Regulator effects of interleukin-4 on tumor infiltrating lymphocytes (TIL)].Semantic proximity Read ↗

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.